VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
ASSA ABLOY AB vs AstraZeneca PLC
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
ASSA ABLOY AB
ASSA-B · Nasdaq Stockholm
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into ASSA ABLOY AB's moat claims, evidence, and risks.
View ASSA-B analysisAstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisComparison highlights
- Moat score gap: ASSA ABLOY AB leads (76 / 100 vs 71 / 100 for AstraZeneca PLC).
- Segment focus: ASSA ABLOY AB has 5 segments (32.9% in Entrance Systems); AstraZeneca PLC has 6 segments (41% in Oncology).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
- Moat breadth: ASSA ABLOY AB has 4 moat types across 2 domains; AstraZeneca PLC has 4 across 3.
Primary market context
ASSA ABLOY AB
Entrance Systems
Entrance automation and industrial door solutions (pedestrian automatic doors, industrial doors, loading dock equipment, service/maintenance)
Global
Commercial/industrial facilities via distributors, installers and service channels
OEM + service/maintenance provider
32.9%
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Side-by-side metrics
Moat coverage
Shared moat types
ASSA ABLOY AB strengths
AstraZeneca PLC strengths
Segment mix
ASSA ABLOY AB segments
Full profile >Opening Solutions EMEIA
Oligopoly
Opening Solutions Americas
Oligopoly
Opening Solutions Asia Pacific
Competitive
Global Technologies
Oligopoly
Entrance Systems
Oligopoly
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.